Research programme: NEXI 300 series - NexImmune
Alternative Names: NEXI-300; NEXI-300 series - NexImmuneLatest Information Update: 28 Aug 2023
At a glance
- Originator NexImmune
- Class Anti-infectives; Immunotherapies
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Infections
Most Recent Events
- 22 Aug 2023 Preclinical trials in Infections in USA (Parenteral) (NexImmune pipeline, August 2023)